2482. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
作者: Yaling Han.;Jincheng Guo.;Yang Zheng.;Hongyun Zang.;Xi Su.;Yu Wang.;Shaoliang Chen.;Tiemin Jiang.;Ping Yang.;Jiyan Chen.;Dongju Jiang.;Quanmin Jing.;Zhenyang Liang.;Haiwei Liu.;Xin Zhao.;Jing Li.;Yi Li.;Bo Xu.;Gregg W Stone.; .
来源: JAMA. 2015年313卷13期1336-46页
The safety and efficacy of bivalirudin compared with heparin with or without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI) are uncertain.
2484. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.
作者: Yong Huo.;Jianping Li.;Xianhui Qin.;Yining Huang.;Xiaobin Wang.;Rebecca F Gottesman.;Genfu Tang.;Binyan Wang.;Dafang Chen.;Mingli He.;Jia Fu.;Yefeng Cai.;Xiuli Shi.;Yan Zhang.;Yimin Cui.;Ningling Sun.;Xiaoying Li.;Xiaoshu Cheng.;Jian'an Wang.;Xinchun Yang.;Tianlun Yang.;Chuanshi Xiao.;Gang Zhao.;Qiang Dong.;Dingliang Zhu.;Xian Wang.;Junbo Ge.;Lianyou Zhao.;Dayi Hu.;Lisheng Liu.;Fan Fan Hou.; .
来源: JAMA. 2015年313卷13期1325-35页
Uncertainty remains about the efficacy of folic acid therapy for the primary prevention of stroke because of limited and inconsistent data.
|